Evidence map›Paper›PMID 33478587›Full record

ArticleCancer & metabolism2021

Intracellular arginine-dependent translation sensor reveals the dynamics of arginine starvation response and resistance in ASS1-negative cells.

Leonard C Rogers, Jing Zhou, Adriana Baker, Charles R Schutt, Prashanta K Panda, Brian A Van Tine

Open access · goldAbstract read
In one paragraph

Article in Cancer & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation-Induced Apoptosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  4. Review
  5. Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Leonard C RogersDivision of Medical Oncology, Washington University in St. Louis, St. Louis, Missouri, 63110, USA.
Jing ZhouDivision of Medical Oncology, Washington University in St. Louis, St. Louis, Missouri, 63110, USA.
Adriana BakerDivision of Medical Oncology, Washington University in St. Louis, St. Louis, Missouri, 63110, USA.
Charles R SchuttDivision of Medical Oncology, Washington University in St. Louis, St. Louis, Missouri, 63110, USA.
Prashanta K PandaDivision of Medical Oncology, Washington University in St. Louis, St. Louis, Missouri, 63110, USA.
Brian A Van TineDivision of Medical Oncology, Washington University in St. Louis, St. Louis, Missouri, 63110, USA. bvantine@wustl.edu.ORCID http://orcid.org/0000-0003-4572-6668
Washington University in St. Louis · USNanchang University · CNSt. Louis Children's Hospital · USUniversity of Nevada, Las Vegas · US

Funding

USING ARGININE METABOLIC THERAPIES FOR SARCOMAR01CA227115 · NCI · WASHINGTON UNIVERSITY · PI VAN TINE, BRIAN ANDREW · 2019 to 2023
$1.8M
NCI NIH HHS R01 CA227115NCI NIH HHS R01-CA227115
6 · The paper itself

Abstract

backgroundMany cancers silence the metabolic enzyme argininosuccinate synthetase 1 (ASS1), the rate-limiting enzyme for arginine biosynthesis within the urea cycle. Consequently, ASS1-negative cells are susceptible to depletion of extracellular arginine by PEGylated arginine deiminase (ADI-PEG20), an agent currently being developed in clinical trials. As the primary mechanism of resistance to arginine depletion is re-expression of ASS1, we sought a tool to understand the temporal emergence of the resistance phenotype at the single-cell level.

methodsA real-time, single-cell florescence biosensor was developed to monitor arginine-dependent protein translation. The versatile, protein-based sensor provides temporal information about the metabolic adaptation of cells, as it is able to quantify and track individual cells over time.

resultsEvery ASS1-deficient cell analyzed was found to respond to arginine deprivation by decreased expression of the sensor, indicating an absence of resistance in the naïve cell population. However, the temporal recovery and emergence of resistance varied widely amongst cells, suggesting a heterogeneous metabolic response. The sensor also enabled determination of a minimal arginine concentration required for its optimal translation.

conclusionsThe translation-dependent sensor developed here is able to accurately track the development of resistance in ASS1-deficient cells treated with ADI-PEG20. Its ability to track single cells over time allowed the determination that resistance is not present in the naïve population, as well as elucidating the heterogeneity of the timing and extent of resistance. This tool represents a useful advance in the study of arginine deprivation, while its design has potential to be adapted to other amino acids.

Indexed as

ArginineArginine deiminaseArgininosuccinate synthetase 1ASS1BiosensorSarcomaSensorTumor heterogeneity

Identifiers

PMID33478587
PMCPMC7818940
OpenAlexW3123704882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.